Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04197999 · ClinicalTrials.gov registry record · Phase 1
A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer
A Phase 1 study, sponsored by GlycoMimetics Incorporated.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT04197999: Clinical Trial Phase 1 study, sponsored by GlycoMimetics Incorporated.
NCT04197999 is a Phase 1 study that was terminated before completion, run by GlycoMimetics Incorporated. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04197999, a Phase 1 study, was terminated before completion, sponsored by GlycoMimetics Incorporated.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This trial is being conducted to investigate the safety, tolerability, pharmacokinetics (the effect the body has on the drug), and pharmacodynamics (the effect the drug has on the body) of GMI-1359 when given with standard-of-care treatment to subjects with HR+ metastatic breast cancer.
Interventions
- DRUG GMI-1359
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-11-21 |
| Est. Completion | 2021-08-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04197999
The ClinicalTrials.gov registry entry for NCT04197999 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlycoMimetics Incorporated, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GMI-1359 is the first listed.
NCT04197999 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04197999 about?
NCT04197999 is a clinical study titled "A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer". This trial is being conducted to investigate the safety, tolerability, pharmacokinetics (the effect the body has on the drug), and pharmacodynamics (the effect the drug has on the body) of GMI-1359 when given with standard-of-care treatment to subjects with HR+ metastatic breast cancer.
What is the current status of trial NCT04197999?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2019-11-21. Estimated completion is 2021-08-25.
What interventions are being tested in trial NCT04197999?
The interventions under investigation include: GMI-1359 (DRUG).
Who is sponsoring clinical trial NCT04197999?
This trial is sponsored by GlycoMimetics Incorporated, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.